ARA-290 protocol
ARA-290 (cibinetide, erythropoietin-derived peptide). Dosing on this page comes from a published human trial or an approved product label, cited below.
How ARA-290 works
An 11-amino-acid peptide derived from the helix-B domain of erythropoietin. It engages the innate repair receptor without the erythropoietic activity of EPO, so it does not raise haematocrit.
ARA-290 dosing schedule
From the phase 2 trial in sarcoidosis-associated small-fibre neuropathy, one of the few compounds in this category with genuine human trial dosing.
| Phase | Amount | Frequency | Notes |
|---|---|---|---|
| Trial arm | 4 mg | Daily, subcutaneous | The amount used in the sarcoidosis small-fibre neuropathy trial. |
Study length: 28 days in the phase 2 trial.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for ARA-290: Not stocked by our featured supplier.
Storage and stability
Reported effects
- Reported as well tolerated in the phase 2 work, with no increase in haematocrit — the specific advantage over EPO itself.
- Evidence base is small and indication-specific.
Sourcing ARA-290
Our featured supplier does not stock this compound, and we are not going to point you at a vendor we have not looked at. Use the COA checklist on whoever you do buy from, and check the batch number on the certificate against the vial you receive.
